EMA sets June target for finalizing trial data disclosure policy
This article was originally published in SRA
Executive Summary
In an attempt to assuage pharmaceutical industry fears about the disclosure of commercially confidential information (CCI), the European Medicines Agency is looking at the best way of deleting such information from clinical trial data that would be released under the agency's controversial draft policy on proactive disclosure1,2. The EMA says it plans to present the final policy together with an implementation plan to its management board for endorsement at the next meeting of the board in June.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.